

sent by email: [REDACTED]

[REDACTED]
Associate Director Highly Specialised Technologies
Centre for Health Technology Evaluation

1 August 2019

Dear [REDACTED]

**Final Evaluation Document withdrawal - metreleptin for treating lipodystrophy
[ID861]**

Thank you for your letter of 31 July 2019 in relation to the metreleptin appeal. I consider the HST committee's request in this matter to be eminently sensible and I agree with the proposal to retract the Final Evaluation Document (FED) and postpone the evaluation until the company is ready to resubmit its case for review. I have therefore stopped the appeal process at this point. We will contact the appellants with my decision. Any further appeal connected with this evaluation will follow due process after completion of a second FED.

Yours sincerely

Tim Irish
Vice Chair
National Institute for Health and Care Excellence